“The following SlideShare are the latest Elsevier metrics of our repurposing article. Good, bad or other research news? In future these kinds of metrics will be used to assess whether, or not, our outputs have impact. We believe the issue of repurposing is still being ignored and our article highlights what needs to be done to address this issue. At present we have had zero impact.
We need an open and very public debate on this issue in particular with regard to the cost of MS drugs. The study below shows that since the launch of IFNbeta and GA in the 90’s the cost of these innovator drugs have increase 5-6 fold. How come? The MS DMT market in the US is looking increasingly like a cartel, it is clear that market forces are not having the desired effect.
Maybe the repurposing of cheaper drugs will act as a brake on this unsustainable trend? It is interesting that the same increase in drug price is not happening to the same extent in the field of rheumatoid arthritis. It is only a matter of time before politicians and payers take action.”
Giovannoni et al. The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? Mult Scler Relat Disord. 2015 Jan;4(1):3-5.
Hartung et al. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology. 2015 May 26;84(21):2185-92.
OBJECTIVE: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices.
CONCLUSIONS: MS DMT costs have accelerated at rates well beyond inflation and substantially above rates observed for drugs in a similar biologic class. There is an urgent need for clinicians, payers, and manufacturers in the United States to confront the soaring costs of DMTs.